Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
-0.14
%
-3,03%
Latest
4.48
High
4.7
Low
4.46
Volume
7 576
Turnover (SEK)
34 678
Value (MSEK)
53,3

Board

CEO

  • Nils Brünner

Chairman Of The Board

  • Jørgen Bardenfleth

Board

  • Carl Borrebäck
  • Peter Høngaard
  • Thomas Feldthus

Videos

Key Numbers

*Compiled data from Inquiry Financial

Upcoming reports

  • 2019-08-22 Delårsrapport 2019-Q2

  • 2019-11-19 Delårsrapport 2019-Q3